Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial)

In the CONFIDENCE trial, starting finerenone and an SGLT2 inhibitor together cut urine protein more than either drug alone, and this benefit held whether or not patients were already taking a GLP-1 weight/diabetes medicine.